` CVM (CEL-SCI Corp) vs S&P 500 Comparison - Alpha Spread

C
CVM
vs
S&P 500

Over the past 12 months, CVM has underperformed S&P 500, delivering a return of -91% compared to the S&P 500's +13% growth.

Stocks Performance
CVM vs S&P 500

Loading
CVM
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CVM vs S&P 500

Loading
CVM
S&P 500
Difference
www.alphaspread.com

Performance By Year
CVM vs S&P 500

Loading
CVM
S&P 500
Add Stock

Competitors Performance
CEL-SCI Corp vs Peers

S&P 500
CVM
ABBV
AMGN
GILD
VRTX
Add Stock

CEL-SCI Corp
Glance View

Market Cap
20.4m USD
Industry
Biotechnology

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.

CVM Intrinsic Value
Not Available
C
Back to Top